Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402196 | 0.90 | GAA (0.53) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL6774538 | 0.83 | CES2 (0.61) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL11214243 | 0.83 | GAA (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL27602661 | 0.83 | GAA (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL1274051 | 0.82 | CES2 (0.50) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL1822227 | 0.81 | GAA (0.49) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL7288270 | 0.81 | GAA (0.49) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL7470109 | 0.81 | GAA (0.49) | GAACES2CES1KCNN4CNR2 | |
| SCHEMBL14270923 | 0.80 | CES2 (0.48) | GAACES2CES1CNR2ALDH1A1 | |
| SCHEMBL17968495 | 0.78 | GAA (0.58) | GAACES2CES1KCNN4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957498-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | MethylGene Inc. (CA) | 2008-08-20 | — | — | EP | claimed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1761268-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | GAA 1146/4885CES2 4799/4885CES1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.